NEW YORK, Nov. 28, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey.
Under terms of the agreement, the New Jersey Center for Biomaterials will be conducting a series of research projects that will further define the unique characteristics and properties of IntelliCell's proprietary cellular population. The work will be conducted on behalf of IntelliCell under the direction of Professor Joachim Kohn, the noted researcher and inventor who directs the New Jersey Center for Biomaterials.
Initial research will focus on documenting any differences between IntelliCell's proprietary cellular population and similar cell populations isolated from human adipose tissue using conventional methods of cell isolation. After successful completion of the initial phases of the clinical research, the Company hopes to engage the New Jersey Center for Biomaterials in development projects that may lead to bioengineered products containing the proprietary IntelliCell cellular population and products under development at the New Jersey Center for Biomaterials.
Dr. Steven Victor, Chairman and CEO of IntelliCell stated, "We are very pleased to be working with Professor Kohn and the New Jersey Center for Biomaterials. Our vision for the future includes a number of bio-applications whereby we can apply our technology to exciting new areas in regenerative medicine and work with top tier research institutions in the United States."
Professor Joachim Kohn, Director of the New Jersey Center for Biomaterials at Rutgers,-The State University of New Jersey added, "This is a truly exciting opportunity for us. We have a number of highly advanced scaffolds for regenerative therapies (e.g. re-growing bone, nerve, and skin), and we expect that Intel
|SOURCE IntelliCell BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved